The present findings are further supported by Nannuru et al, who found that treatment with MMP13 antisense oligonucleotides reduces mammary tumor-induced osteolysis at the tumor-bone interface, where they also found elevated MMP13 [17]. Here, MMP13 is linked to breast cancer.